Brokerages Set Definitive Healthcare Corp. (NASDAQ:DH) Target Price at $5.35

Definitive Healthcare Corp. (NASDAQ:DH) has been given a consensus rating of “Hold” by the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $5.35.

A number of research firms have commented on DH. Stephens began coverage on shares of Definitive Healthcare in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. The Goldman Sachs Group cut their price target on shares of Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Barclays cut their price target on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a report on Monday, March 3rd.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH opened at $2.79 on Friday. The company’s fifty day moving average price is $4.22 and its 200 day moving average price is $4.33. Definitive Healthcare has a 12 month low of $2.55 and a 12 month high of $8.35. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The firm has a market capitalization of $315.02 million, a P/E ratio of -0.90, a P/E/G ratio of 4.06 and a beta of 1.51.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $62.29 million for the quarter, compared to analyst estimates of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. As a group, sell-side analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Irenic Capital Management LP grew its position in shares of Definitive Healthcare by 9.2% in the fourth quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company’s stock valued at $28,783,000 after purchasing an additional 590,009 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Definitive Healthcare by 36.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock valued at $27,058,000 after purchasing an additional 1,626,813 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Definitive Healthcare by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company’s stock valued at $7,661,000 after purchasing an additional 23,410 shares during the last quarter. State Street Corp grew its position in shares of Definitive Healthcare by 29.4% in the third quarter. State Street Corp now owns 1,399,729 shares of the company’s stock valued at $6,257,000 after purchasing an additional 317,952 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Definitive Healthcare by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company’s stock valued at $5,231,000 after purchasing an additional 39,938 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.